European Commission Explains Impact Of EU Pharma Review On SMEs & Non-Profit Entities

The EU pharmaceutical revision package includes proposals that will have a direct impact on smaller firms, including a targeted regulatory and procedural support scheme.

big and small execs
Smaller firms will have their own benefits from the EU pharma review • Source: Shutterstock

Something that may be overlooked in the European Commission’s package of proposals for revising the EU pharmaceutical legislation is a new set of measures targeted specifically at small and medium-sized enterprises (SMEs) and not-for-profit entities.

SMEs have long been seen as an important pillar of the pharmaceutical industry in Europe as often “they are the ones developing the most innovative medicines because they take the risks when sometimes the bigger ones do not,”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography